Tenet Healthcare's Raised Guidance Now Has to Survive Without the Medicaid Cushion

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Tenet Healthcare reports before market open, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

Historical price behavior around earnings reveals significant volatility, with an average absolute Day 0 move of 9.28% and Day 0 range of 12.02%. The most dramatic recent reaction came in February 2026, when the stock surged 17.26% on Day 0 with an intraday range exceeding 22%, followed by more modest follow-through. The July 2026 earnings saw a relatively muted Day 0 move of just 1.88%, but Day +1 delivered a powerful 17.17% surge as the market fully digested the 50% earnings beat.

The pattern suggests THC tends to see its largest moves on the initial reaction day, with Day +1 averaging 4.88% and typically serving as either continuation of the initial direction or modest mean reversion. Notably, the stock has shown a tendency toward positive Day 0 moves in recent quarters, with five of the last eight earnings dates producing gains on the announcement day. The 5.30% average Day +1 range indicates continued active trading in the follow-through session, suggesting investors should expect elevated volatility to persist beyond the initial reaction.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 9.78% through the November 20 expiration, closely aligned with the 9.28% average historical Day 0 move. This suggests options traders are anticipating volatility consistent with THC's recent earnings pattern, neither pricing in an outsized reaction nor expecting a muted response. The $26.27 implied move establishes a range of $242.24 to $294.77, with the upper bound approaching analyst price targets.

Part 3: What Analysts Are Saying

Analyst sentiment remains decidedly bullish on Tenet Healthcare, with the current consensus rating of 4.52 reflecting strong buy conviction despite a slight deterioration from 4.61 one month ago. The analyst community shows 16 strong buy ratings, 3 moderate buys, and 4 holds, with no sell recommendations, indicating broad confidence in the company's prospects even as some caution has crept into the outlook.

The deteriorated sentiment trend over the past month reflects one analyst downgrading from strong buy, likely reflecting valuation concerns after the stock's strong run and questions about sustainability of the exceptional earnings beats. However, the overwhelming majority of analysts maintain aggressive buy ratings, suggesting most view any near-term headwinds as manageable within the context of THC's diversified platform and operational momentum.

The consensus price target of $286.64 implies approximately 6.7% upside from the current price of $268.50, a relatively modest premium that reflects the stock's strong year-to-date performance and the market's move toward fair value. The range of targets spans from $260.00 to $315.00, with the high estimate suggesting some analysts see potential for significant additional appreciation if execution continues to exceed expectations. The low target of $260.00 sits roughly 3% below current levels, indicating even the most cautious analysts see limited downside risk from current valuations, though this also suggests the margin of safety has compressed considerably after the stock's 31% year-to-date advance.

Part 4: Technical Picture

Tenet Healthcare enters earnings with exceptionally strong technical momentum, as the Barchart Technical Opinion has strengthened dramatically to 100% Buy from 56% Buy one month ago and 88% Buy just last week. This rapid improvement in the signal reflects powerful upside momentum that has accelerated into the earnings release, though it also suggests the stock may be technically extended in the very near term.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates powerful near-term momentum is driving the stock higher heading into earnings
• Medium-term (100% Buy): Strong buy signal confirms the uptrend is well-established across intermediate timeframes, not just a short-term spike
• Long-term (100% Buy): Maximum long-term buy reading reflects the stock's sustained advance over the past year and structural uptrend remains intact

Strong and Strengthening — The combination of maximum strength across all timeframes with a strengthening directional bias creates a technically supportive environment for earnings, though the uniformly bullish readings also suggest limited room for further technical improvement and potential vulnerability to any disappointment.

The stock is currently trading above its 5-day moving average of $267.72 but below the 10-day at $268.88, indicating some very near-term consolidation after recent strength.

THC trades above all major moving averages from the 20-day ($265.54) through the 200-day ($219.46), confirming the structural uptrend remains firmly intact. The stock sits approximately 22.3% above its 200-day moving average, reflecting the powerful year-to-date advance but also suggesting extended conditions that could amplify downside risk if earnings disappoint. The 52-week range of $157.58 to $283.05 shows the stock trading in the upper third of its annual range, just 5.1% below the August high. The technical setup is supportive heading into earnings, with momentum clearly favoring bulls, but the lack of nearby support levels and extended positioning means any negative surprise could trigger outsized profit-taking as recent buyers rush to protect gains.